Welcome to our dedicated page for PepGen SEC filings (Ticker: PEPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PepGen Inc. filings document the regulatory record of a clinical-stage biotechnology company developing Enhanced Delivery Oligonucleotide therapies for neuromuscular and neurological diseases. Its Form 8-K disclosures cover financial results, corporate presentations, clinical data updates for PGN-EDODM1, FDA-related regulatory matters involving FREEDOM2-DM1, and other business updates tied to its development pipeline.
The company’s proxy materials describe annual meeting matters, director elections, auditor ratification, board structure, executive compensation and stockholder voting mechanics. Other filings address officer appointments, inducement grants, stock-option plans, option repricing, common-stock compensation arrangements and related governance approvals. Together, the filings outline PepGen’s clinical-development disclosures, capital and equity incentive structure, risk-facing regulatory events and public-company governance practices.